HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DoJ Casts Criminal Charge Net For Supplements Making STD Claims

This article was originally published in The Rose Sheet

Executive Summary

DoJ announces misdemeanor charges against firm warned about making unapproved claims of treating STDs and cancer for products marketed as dietary supplements, while FDA continues finding the banned weight loss drug sibutramine in products.

You may also be interested in...



Cancer, HIV 'Cure' Claims Prompt Consent Decree For Vibrant Life Firm

DoJ filed the complaint and numerous others following more than a year of investigations by multiple federal agencies in the supplement market, with some leading to criminal charges. Clifford Woods continued making cancer, HIV, arthritis and other disease claims for its Vibrant Life supplements following a 2013 warning.

Prosecutions Send Spiked Consumer Health Product Marketers To Prison

The convictions in federal district courts ought to interest supplement industry stakeholders long calling for DoJ and FDA to prosecute criminal charges stemming from investigations of spiked supplements, but likely will also prompt calls for authorities to drill down with charges against the sources of the products.

Weight Loss Products Provide Ample Targets In FDA War On Spiked Supplements

FDA finds four weight loss products that contain potentially dangerous undeclared ingredients, including DMAA and sibutramine. The agency also continues to warn about bee pollen with undeclared ingredients.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS108444

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel